Search Results

There are 683 results for: content related to: Effects of omalizumab on markers of inflammation in patients with allergic asthma

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Article first published online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  3. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

    Allergy

    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Article first published online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  4. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Article first published online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  5. You have free access to this content
    Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

    Allergy

    Volume 66, Issue 5, May 2011, Pages: 671–678, J. Bousquet, Z. Siergiejko, E. Świebocka, M. Humbert, K. F. Rabe, N. Smith, J. Leo, C. Peckitt, R. Maykut and G. Peachey

    Article first published online : 21 JAN 2011, DOI: 10.1111/j.1398-9995.2010.02522.x

  6. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Article first published online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x

  7. You have free access to this content
    Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 61–76, Philip J. Lowe, Stacey Tannenbaum, Aurelie Gautier and Pablo Jimenez

    Article first published online : 26 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03401.x

  8. You have free access to this content
    The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

    Allergy

    Volume 65, Issue 9, September 2010, Pages: 1141–1148, J. D. Campbell, D. E. Spackman and S. D. Sullivan

    Article first published online : 10 FEB 2010, DOI: 10.1111/j.1398-9995.2010.02336.x

  9. You have free access to this content
    A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab

    British Journal of Clinical Pharmacology

    Volume 63, Issue 5, May 2007, Pages: 548–561, Naoto Hayashi, Yuko Tsukamoto, William M. Sallas and Philip J. Lowe

    Article first published online : 10 NOV 2006, DOI: 10.1111/j.1365-2125.2006.02803.x

  10. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 701–708, J. G. Ayres, B. Higgins, E. R. Chilvers, G. Ayre, M. Blogg and H. Fox

    Article first published online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00533.x

  11. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy

    Allergy

    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Article first published online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  12. You have free access to this content
    Anti-IgE in severe persistent allergic asthma

    Respirology

    Volume 12, Issue s3, November 2007, Pages: S22–S28, Howard FOX

    Article first published online : 18 OCT 2007, DOI: 10.1111/j.1440-1843.2007.01016.x

  13. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Article first published online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  14. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Article first published online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x

  15. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

    Pediatric Allergy and Immunology

    Volume 24, Issue 5, August 2013, Pages: 427–433, Matthias Volkmar Kopp, Eckard Hamelmann, Meike Bendiks, Stefan Zielen, Wolfgang Kamin, Karl-Christian Bergmann, Christian Klein, Ulrich Wahn and for The DUAL study group

    Article first published online : 25 JUN 2013, DOI: 10.1111/pai.12098

  16. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 8, Issue 12, December 2010, Pages: 990–998, Peter Maximilian Heil, Dieter Maurer, Brigitte Klein, Thomas Hultsch and Georg Stingl

    Article first published online : 30 JUL 2010, DOI: 10.1111/j.1610-0387.2010.07497.x

  17. You have free access to this content
    The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children

    Allergy

    Volume 59, Issue 9, September 2004, Pages: 973–979, C. Rolinck-Werninghaus, E. Hamelmann, T. Keil, M. Kulig, K. Koetz, B. Gerstner, J. Kuehr, S. Zielen, U. Schauer, W. Kamin, A. Von Berg, J. Hammermann, B. Weinkauf, G. Weidinger, S. Stenglein, U. Wahn and The Omalizumab Rhinitis Study Group

    Article first published online : 2 AUG 2004, DOI: 10.1111/j.1398-9995.2004.00552.x

  18. The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody

    Clinical & Experimental Allergy

    Volume 31, Issue 9, September 2001, Pages: 1344–1351, S. H. Arshad and S. Holgate

    Article first published online : 20 DEC 2001, DOI: 10.1046/j.1365-2222.2001.01162.x

  19. Omalizumab (Xolair) in children with seasonal allergic rhinitis: Leukotriene release as a potential in vitro parameter to monitor therapeutic effects

    Pediatric Allergy and Immunology

    Volume 18, Issue 6, September 2007, Pages: 523–527, Matthias Volkmar Kopp, Stefan Stenglein, Wolfgang Kamin, Frank Friedrichs, Andrea Von Berg, Stefan Zielen, Eckard Hamelmann, Ulrich Wahn and Joachim Kuehr

    Article first published online : 2 AUG 2007, DOI: 10.1111/j.1399-3038.2007.00557.x

  20. You have full text access to this OnlineOpen article
    Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

    Clinical & Experimental Allergy

    Volume 37, Issue 2, February 2007, Pages: 197–207, A. A. Cruz, F. Lima, E. Sarinho, G. Ayre, C. Martin, H. Fox and P. J. Cooper

    Article first published online : 23 JAN 2007, DOI: 10.1111/j.1365-2222.2007.02650.x